Success Metrics

Clinical Success Rate
100.0%

Based on 1 completed trials

Completion Rate
100%(1/1)
Active Trials
3(50%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_1
4
67%
Ph phase_2
1
17%
Ph phase_3
1
17%

Phase Distribution

4

Early Stage

1

Mid Stage

1

Late Stage

Phase Distribution6 total trials
Phase 1Safety & dosage
4(66.7%)
Phase 2Efficacy & side effects
1(16.7%)
Phase 3Large-scale testing
1(16.7%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

1 of 1 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

3

trials recruiting

Total Trials

6

all time

Status Distribution
Active(5)
Completed(1)

Detailed Status

Recruiting3
Not yet recruiting2
Completed1

Development Timeline

Analytics

Development Status

Total Trials
6
Active
3
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 14 (66.7%)
Phase 21 (16.7%)
Phase 31 (16.7%)

Trials by Status

completed117%
recruiting350%
not_yet_recruiting233%

Recent Activity

3 active trials
Showing 5 of 6
recruitingphase_2

A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)

NCT07221500
recruitingphase_1

A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies

NCT05131022
not_yet_recruitingphase_1

Study of NX-5948 in Combination With Other Agents in Adults With B-cell Malignancies

NCT07520006
not_yet_recruitingphase_3

Study of NX-5948 Versus Pirtobrutinib in R/R CLL/SLL

NCT07516093
recruitingphase_1

Relative Bioavailability of NX-5948 Tablets vs Capsules and the Effect of Covariates on the PK of NX-5948 Tablets

NCT06717269
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT07221500Phase 2

A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)

Recruiting
NCT05131022Phase 1

A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies

Recruiting
NCT07520006Phase 1

Study of NX-5948 in Combination With Other Agents in Adults With B-cell Malignancies

Not Yet Recruiting
NCT07516093Phase 3

Study of NX-5948 Versus Pirtobrutinib in R/R CLL/SLL

Not Yet Recruiting
NCT06717269Phase 1

Relative Bioavailability of NX-5948 Tablets vs Capsules and the Effect of Covariates on the PK of NX-5948 Tablets

Recruiting
NCT06691828Phase 1

Absolute Bioavailability, Absorption, Metabolism, Excretion, and Mass Balance Study of [14C] NX-5948

Completed

All 6 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
6